Two recent federal initiatives have catapulted buprenorphine to the forefront of treatment for opioid use disorders.

It’s no secret that SSRIs and SNRIs cause sexual dysfunction (SD) in a large proportion of patients who take them. The exact size of that proportion, though, is difficult to pinpoint with any reliability. Most of the large clinical trials of antidepressants ascertain side effects through spontaneous reports, and research subjects are understandably embarrassed about coming out and complaining about sexual problems.

As clinicians, we need to fully understand the importance of side effects for our patients. The most important problem in psychopharmacology is that patients stop taking their medication sooner or later. And what is the most frequent single reason for their stopping the medication? Side effects. In this interview, Dr. Rajnish Mago discusses important strategies for discussing side effects with patients.

Ideally, an SUD in a health care provider can be recognized as early as possible, before irreparable harm comes to the provider’s career, patients, or family. Overdose and suicide are not uncommon outcomes, and efforts must be focused on preventing these as well as protecting patients.

Ever wish you could improve treatment compliance among your patients who receive buprenorphine? Ever wish you could offer them the benefit of sublingual buprenorphine while avoiding the risk of diversion and abuse? Well, now you can—maybe.

What changes when addressing addiction when the patient is a doctor? When you’re dealing with health care professionals, the defenses common among people struggling with substance abuse are much more sophisticated. Many times a doctor or other highly trained health professional can talk circles around substance abuse counselors. Dr. Ziegler shares her insight on treating health care professionals.

Many chronic pain patients are dealing with psychiatric problems. Pain patients have tremendously high rates of major depressive disorder which is undertreated and underdiagnosed. It's easy to assume that the depression is a reaction to living with chronic pain, but in fact it’s often the other way around. Dr. Michael Robert Clark describes evaluations and treatment methods clinicians can use to address pain management with their patients.

Effective pharmacological treatments for cannabis dependence have eluded the field of addiction psychiatry. It’s not, however, due to a lack of trying. Theoretical connections between cannabinoids and the serotonin system have spurred a number of studies looking at the usefulness of SSRIs and buspirone.

Dialectical behavior therapy (DBT) is well-known for treating borderline personality disorder (BPD) and individuals at high risk for suicide. Two studies have shown that DBT has really good outcomes in terms of reducing substance use. In this interview, Dr. Linehan shares her knowledge of DBT as a treatment method for addiction.

We’ve been hearing for some time now about the FDA’s plans to revise the long-standing categories A, B, C, D, and X designations for risk of using medications in pregnancy. The new rule (referred to as PLLR for Pregnancy and Lactation Labeling Rule) was proposed in 2008, finalized in 2014, and implementation began during the summer of 2015.